Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.49 |
| ▸ | GBA1 | P04062 | 8/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23613270 | 1.00 | HRH4 (0.49) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL19176415 | 1.00 | HRH4 (0.49) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL3549776 | 0.98 | HRH4 (0.48) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL9926328 | 0.94 | HRH4 (0.46) | HRH4HRH3CYP19A1GBA1 | |
| SCHEMBL18493346 | 0.93 | HRH4 (0.54) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL5021139 | 0.93 | HRH4 (0.54) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18493347 | 0.91 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18494157 | 0.91 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL22762136 | 0.91 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 | |
| SCHEMBL18489275 | 0.91 | HRH4 (0.56) | HRH4HRH3CYP19A1GBA1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | AILERON THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9789164-B2 | Peptides comprising non-natural amino acids and methods of making and using the same | LONGEVITY BIOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-8399405-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | NASH HUW M | 2011-10-13 | — | — | US | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225650-A1 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA | HIF1A, HIF1AN, EGLN3 | HRH4 1456/4885HRH3 875/4885CYP19A1 797/4885 |
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885CYP19A1 2366/4885 |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | MCL1, BCL2L1, BCL2L11 | HRH4 4598/4885HRH3 3944/4885CYP19A1 4708/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | HRH4 1806/4885HRH3 1158/4885CYP19A1 2366/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | HRH4 2978/4885HRH3 2750/4885CYP19A1 3662/4885 |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | HRH4 1115/4885HRH3 912/4885CYP19A1 2898/4885 |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | HRH4 4246/4885HRH3 3700/4885CYP19A1 3250/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | HRH4 1851/4885HRH3 2016/4885CYP19A1 1614/4885 |
| US-20110250685-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | SLC29A2, SLC29A1, SLC22A3 | HRH4 4816/4885HRH3 3990/4885CYP19A1 4772/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885CYP19A1 2899/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | HRH4 4246/4885HRH3 3700/4885CYP19A1 3250/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | HRH4 4334/4885HRH3 3879/4885CYP19A1 3811/4885 |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | HRH4 2561/4885HRH3 2159/4885CYP19A1 2283/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH4 3193/4885HRH3 1490/4885CYP19A1 4266/4885 |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | MCL1, BCL2L1, BCL2L11 | HRH4 4598/4885HRH3 3944/4885CYP19A1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.